Virax Biolabs Group Ltd director Nelson M. Haight reported his initial beneficial ownership of stock options in the company. The holdings include options over 2,000 Ordinary Shares with a $15.40 exercise price expiring on November 17, 2032, granted under the 2023 Equity Incentive Plan.
He also holds options over 10,000 Ordinary Shares with a $6.00 exercise price expiring on April 18, 2033, 10,000 options at $0.68 expiring on April 18, 2034, and 10,000 options at $0.88 expiring on April 8, 2035. Footnotes state these options vest in scheduled halves or thirds on specified future dates, becoming exercisable as they vest.
Virax Biolabs Group Ltd director and Chief Operating Officer Nigel William McCracken filed an initial Form 3 disclosing stock option holdings. He holds options over 20,000 ordinary shares at an exercise price of $3.6000 expiring on September 1, 2033, 50,000 shares at $0.6800 expiring on April 18, 2034, and two grants over 20,584 and 29,416 shares at $0.8800 expiring on April 8, 2035. Footnotes state these options were granted under the company’s 2023 and 2024 Equity Incentive Plans and vest in equal thirds over three years, with vested portions becoming exercisable upon vesting.
Virax Biolabs Group Limited reported the results of its 2025 adjourned annual meeting of shareholders. With a quorum deemed present at the reconvened meeting, shareholders approved five key items. They ratified Reliant CPAs PC as auditor for the year ending March 31, 2026 and elected all five director nominees. Shareholders also approved a share consolidation of ordinary shares on a one-for-ten to one-for-fifteen basis, increasing par value per share accordingly. They adopted a new fourth amended and restated memorandum and articles of association to reflect revised authorized share capital, effective with the consolidation. In addition, shareholders approved a 2026 Equity Incentive Plan and UK Sub-Plan reserving 2,000,000 ordinary shares for issuance.
Virax Biolabs Group Ltd Chief Executive Officer Foster James Alexander Cunliffe filed an initial statement of beneficial ownership, showing 287,987 Ordinary Shares held directly plus multiple stock option awards over additional Ordinary Shares. These options carry exercise prices ranging from $50.00 down to $0.68 per share and expire between 2032 and 2035. Footnotes explain that the grants were made under the company’s 2023 and 2024 equity incentive plans, with vesting schedules that generally occur in equal annual installments over three years, becoming exercisable as they vest.
Virax Biolabs Group Ltd director Norton Evan Michael filed an initial statement of beneficial ownership, reporting stock option holdings over the company’s ordinary shares. He holds options for 2,000 shares at an exercise price of $6.0000 expiring on July 20, 2032, and 10,000 shares at $6.0000 expiring on April 18, 2033. He also holds 10,000 options at $0.6800 expiring on April 18, 2034 and 10,000 options at $0.8800 expiring on April 8, 2035. Footnotes state these options were granted between July 20, 2022 and April 8, 2025 under the company’s equity incentive plans, with vesting in halves or thirds and becoming exercisable upon vesting.
Virax Biolabs Group Ltd filed an initial insider ownership report for Chief Financial Officer Jason Davis on Form 3. This filing serves as a baseline disclosure of his beneficial ownership position when he became a reporting insider. The data provided does not list any specific shareholdings or report any buy, sell, or option exercise transactions.
Virax Biolabs Group Ltd director Miller Iain David filed a Form 3, which is an initial statement of beneficial ownership. This filing records his starting equity position as an insider of the company but does not report any stock purchases, sales, option exercises, or other transactions.
Virax Biolabs Group Ltd reports an institutional beneficial ownership filing showing 9.99% of ordinary shares, equal to 823,909 shares, held by Armistice Capital, LLC and attributed to Steven Boyd as managing member, with an ownership reporting date of 12/31/2025.
The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that voting and dispositive power are exercised jointly (shared power: 823,909 shares). The Master Fund is identified as the entity entitled to proceeds or dividends.
Virax Biolabs Group Limited has called its 2025 annual general meeting for March 11, 2026, in Glasgow. Shareholders are being asked to ratify Reliant CPA PC as auditor, re-appoint five current directors, approve a share consolidation, adopt updated governing documents, approve a new equity plan, and authorize potential adjournment.
The proposed share consolidation would combine between 10 and 15 existing ordinary shares into 1 share on or before July 11, 2026, with fractional shares rounded up. This is intended to help the company satisfy Nasdaq’s minimum $1.00 bid price requirement after receiving a noncompliance notice in July 2025.
The board is also seeking approval of a new 2026 Equity Incentive Plan and UK Sub-Plan reserving 2,000,000 ordinary shares for awards. Existing 2022–2024 plans cover smaller pools, much of which is already granted. The board unanimously recommends voting “FOR” all six proposals.
Virax Biolabs Group Limited has filed a resale registration covering up to 25,875,000 ordinary shares for existing investors. These shares are issuable from a December 2025 private placement and consist of 12,500,000 shares from Pre-Funded Warrants, 12,500,000 shares from Preferred Investment Options, and 875,000 shares from Placement Agent Warrants. As of December 17, 2025, Virax had 7,423,432 ordinary shares outstanding.
Virax is an emerging growth immunology-focused biotechnology company developing T cell diagnostics and immune profiling tools, including its in-development ViraxImmune™ assay and ImmuneSelect research-use-only portfolio. In the related private placement with Armistice Capital, Virax raised approximately $5,000,000 in gross proceeds and issued long-dated, low-priced warrants and options. The selling shareholders will receive all proceeds from resales, while Virax may receive additional cash only if these warrants and options are exercised.